Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985200 | 0.88 | RAB9A (0.50) | RAB9AGAAKDM4EALDH1A1HPGDS | |
| SCHEMBL9609104 | 0.83 | RAB9A (0.43) | RAB9AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL11242632 | 0.82 | KDM4E (0.50) | RAB9AGAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL27511626 | 0.81 | HSP90AA1 (0.49) | GAAKDM4EALDH1A1MAPTCASP1 | |
| SCHEMBL17055639 | 0.80 | PDE4A (0.48) | RAB9AGAAKDM4EALDH1A1MAPT | |
| SCHEMBL28319223 | 0.77 | PDE4A (0.50) | RAB9APOLBLMNAPDE4APDE4B | |
| SCHEMBL20654206 | 0.77 | PDE4A (0.46) | RAB9AGAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9496929 | 0.75 | GSTO1 (0.44) | RAB9AALDH1A1HPGDSPDE4APDE4B | |
| SCHEMBL4382163 | 0.75 | RAB9A (0.49) | RAB9AGAAKDM4EALDH1A1HPGDS | |
| SCHEMBL2830618 | 0.73 | MEN1 (0.51) | KDM4ELMNAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012069175-A1 | NEW PYRAZOLE DERIVATIVES HAVING CRTH2 ANTAGONISTIC BEHAVIOUR | ALMIRALL, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| EP-2457900-A1 | New pyrazole derivatives having CRTh2 antagonistic behaviour | Almirall, S.A. (ES) | 2012-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | RAB9A 357/4885GAA 148/4885KDM4E 1590/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | RAB9A 357/4885GAA 148/4885KDM4E 1590/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | RAB9A 357/4885GAA 148/4885KDM4E 1590/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | RAB9A 357/4885GAA 148/4885KDM4E 1590/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | RAB9A 357/4885GAA 148/4885KDM4E 1590/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | RAB9A 357/4885GAA 148/4885KDM4E 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.